Altamira Therapeutics is dedicated to unlocking the potential of RNA delivery beyond the liver using its proprietary delivery platform OligoPhore™ / SemaPhore™. The platform is used in Altamira’s flagship programs, AM-401, for the treatment of KRAS driven cancer, and AM-411, for the treatment of rheumatoid arthritis, as well as by partners for extrahepatic delivery and strong endosomal release of their proprietary RNA molecules.
Altamira Therapeutics
